Navigation Links
Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Date:8/27/2007

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at two upcoming conferences in early September:

The Thomas Weisel Partners Healthcare Conference 2007 on Wednesday, September 5, at 4:25 p.m. Eastern time at the Four Seasons Hotel in Boston.

BioCentury's "Newsmakers in the Biotech Industry" conference on Thursday, September 6, at 4:00 p.m. Eastern time at the Millennium Broadway Hotel in New York.

Dr. McMahon will provide a corporate overview, including an update on the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of each presentation will be available on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... COLORADO (PRWEB) , ... April 21, 2017 , ... ... Awards recognized outstanding manufactures in 10 categories with over 30 nominees and well ... in Manufacturing presented the new award and the event was hosted by CompanyWeek ...
(Date:4/21/2017)... ANAHEIM, California, and BELLINGHAM, Washington, USA (PRWEB) , ... ... ... of photonics technologies for sensing, imaging, and related applications were the focus of ... Defense and Commercial Sensing 2017 in Anaheim. , Sponsored by SPIE, ...
(Date:4/21/2017)... ... ... Frederick Innovative Technology Center, Inc. (FITCI), a business incubator ... a $77,518 grant from the Rural Maryland Council (RMC) to support refurbishment of ... incubator. A non-profit corporation, FITCI is a public-private partnership of the governments of ...
(Date:4/20/2017)... INDIANAPOLIS , April 20, 2017  Eli Lilly ... Phase 2 data evaluating galcanezumab for the prevention of ... meeting, which will take place April 22-28, 2017, in ... will present four abstracts at AAN, including safety and ... and factors associated with a reduction in monthly migraine ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):